Category : Healthcare and Pharmaceuticals | Published at : December-2020 | Delivery Format : PDF | Status: Published | Pages : 190
The market for aerosol delivery devices is expected to grow at a CAGR of around 4.3% from 2020 to 2027 and expected to reach the market value of around US$ 47,685.4 Mn by 2027.
An aerosol is a suspension of liquid or solid particles in a carrier gas. Aerosol delivery devices have evolved from the basic pressurized metered-dose inhaler and nebulizer to numerous types of inhalers and devices, including dry powder inhalers, soft mist inhalers, valve holder chambers, and smart inhalers & nebulizers. These devices deliver aerosolized drugs directly into the lungs and have the advantage of higher drug concentration delivered more effectively to the airways along with the reduced systemic adverse effects. Additionally, aerosol drug delivery is painless and convenient and can improve a patient's ability to self-administer medication. Moreover, some drugs are therapeutically active only when inhaled.
Market Dynamics
The increasing usage of aerosol delivery devices like dry powder inhalers, metered-dose inhalers, and nebulizers for the treatment of asthma and COPD is driving the market growth. These devices are also used in non-respiratory diseases such as diabetes, analgesia, and Parkinson’s disease which is also supporting growth. The rising prevalence of respiratory diseases such as COPD, asthma, and cystic fibrosis, surging focus of manufacturers toward the development of portable inhalation devices, rising demand for short-term, effective medication for asthma, and COPD are further bolstering the market value. The increasing geriatric population, technological advancements in inhaler devices, rising adoption of aerosol delivery devices by patients, rapid urbanization coupled with the increasing pollution levels are boosting the demand for aerosol delivery devices. Additionally, government initiatives to spread awareness about COPD and asthma symptoms in developing and underdeveloped economies as well as ongoing R&D activities to develop ideal inhalation therapy are further projected to provide potential opportunities over the estimated period.
On the other side, the complications and side-effects associated with drug inhalation and high cost associated with nebulizers are projected to restrict the market growth over the forecast period from 2020 to 2027.
North America accounted for the maximum revenue share in the global Aerosol Delivery Devices market
In 2019, North America registered a major share in terms of revenue in the aerosol delivery devices market. The presence of major players in the region along with the increasing number of patients with chronic respiratory diseases is supporting the regional market value. Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in America. According to studies, in 2009 around 40.3 million Americans were diagnosed with asthma or COPD. Furthermore, the Asia Pacific region is anticipated to experience the fastest growth with major CAGR during the forecast timeframe from 2020 to 2027.
The players profiled in the report include 3M Company, Aerogen, Inc., Gerresheimer AG, GlaxoSmithKline Plc (GSK), Heitkamp & Thumann KG (H&T Presspart), Iconovo AB, Johnson & Johnson (Actelion Pharmaceuticals Ltd), Koninklijke Philips N.V., Merck & Co., Inc., Merxin Ltd, Metall Zug Group (Clement Clarke International Ltd), Nemera, Recipharm AB (Bespak), Teva Pharmaceutical Industries Limited, and Vectura Group PLC. The major aerosol delivery devices players were involved in strategic developments for escalating the profit share in regional as well as the global market. The major investments were announced in the aerosol delivery devices market for technological advancements in the field.
Market Segmentation
Market By Product
Dry powder inhalers
- Single dose inhalers
- Multi dose inhalers
Metered dose inhalers
- Conventional pressurized inhalers,
- Soft mist inhalers
Nebulizers
- Jet nebulizers
- Ultrasonic wave nebulizers
- Vibrating mesh nebulizers
Market By Application
Asthma
Chronic obstructive pulmonary disease
Cystic fibrosis
Non respiratory diseases
Diabetes
Analgesia
Parkinson’s disease
Market By Distribution Channel
Retail pharmacies
Hospital pharmacies
E-commerce
Market By Geography
North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
Frequently Asked Questions
The market for aerosol delivery devices is expected to reach a market value of around US$ 47,685.4 Mn by 2027.
The aerosol delivery devices market is expected to grow at a CAGR of around 4.3% from 2020 to 2027.
The increasing usage of aerosol delivery devices like dry powder inhalers, metered-dose inhalers, and nebulizers for the treatment of asthma and COPD, rising prevalence of respiratory diseases such as COPD, asthma, and cystic fibrosis, rising demand for short-term, effective medication for asthma, and COPD, increasing geriatric population, technological advancements in inhaler devices, and rapid urbanization coupled with the increasing pollution levels are some of the factors driving the market growth.
COPD held the significant market share in terms of application in the aerosol delivery devices market
3M Company, Aerogen, Inc., Gerresheimer AG, Glaxosmithkline Plc (GSK), Heitkamp & Thumann KG (H&T Presspart), Iconovo AB, Johnson & Johnson (Actelion Pharmaceuticals Ltd), Koninklijke Philips N.V., Merck & Co., Inc., Merxin Ltd, Metall Zug Group (Clement Clarke International Ltd), Nemera, Recipharm AB (Bespak), Teva Pharmaceutical Industries Limited, and Vectura Group PLC are the prominent players in the market.
North America held the major revenue share in the aerosol delivery devices market.
Asia Pacific is expected to be the fastest growing market over the forecast period.
